- Home
- FCO vs ADAP Comparison
FCO vs ADAP Comparison
Compare FCO & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCO
- ADAP
- Stock Information
- Founded
- FCO 1991
- ADAP 2008
- Country
- FCO United Kingdom
- ADAP United Kingdom
- Employees
- FCO N/A
- ADAP N/A
- Industry
- FCO Investment Managers
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- FCO Finance
- ADAP Health Care
- Exchange
- FCO Nasdaq
- ADAP Nasdaq
- Market Cap
- FCO 78.3M
- ADAP 73.1M
- IPO Year
- FCO N/A
- ADAP 2015
- Fundamental
- Price
- FCO $6.19
- ADAP $0.30
- Analyst Decision
- FCO
- ADAP Strong Buy
- Analyst Count
- FCO 0
- ADAP 5
- Target Price
- FCO N/A
- ADAP $1.83
- AVG Volume (30 Days)
- FCO 100.1K
- ADAP 775.4K
- Earning Date
- FCO 01-01-0001
- ADAP 05-13-2025
- Dividend Yield
- FCO 14.96%
- ADAP N/A
- EPS Growth
- FCO N/A
- ADAP N/A
- EPS
- FCO 0.43
- ADAP N/A
- Revenue
- FCO N/A
- ADAP $178,032,000.00
- Revenue This Year
- FCO N/A
- ADAP N/A
- Revenue Next Year
- FCO N/A
- ADAP $69.81
- P/E Ratio
- FCO $12.30
- ADAP N/A
- Revenue Growth
- FCO N/A
- ADAP 195.34
- 52 Week Low
- FCO $4.73
- ADAP $0.20
- 52 Week High
- FCO $6.63
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- FCO 62.53
- ADAP 54.77
- Support Level
- FCO $5.96
- ADAP $0.30
- Resistance Level
- FCO $6.25
- ADAP $0.31
- Average True Range (ATR)
- FCO 0.13
- ADAP 0.02
- MACD
- FCO 0.04
- ADAP 0.01
- Stochastic Oscillator
- FCO 78.57
- ADAP 80.51
About FCO abrdn Global Income Fund Inc.
abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories, Developed Markets, Investment Grade Developing Markets and Sub-Investment Grade Developing Markets.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.